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INTRODUCTION
Notwithstanding the numerous fallacies and the
limitations in interpreting data from the
improper application of, and the unquestioned
reliance on, statistical models (1, 2), my central
question can be stated thus: Can excipients in
the placebo modulate pharmacological effect(s)
sufficiently so that the differential between 
(placebo and active) clinical responses could be
‘tipped’ either in favor of, or against, achieving
statistical significance in placebo controlled
trials?
Admittedly, not all of the so called ‘placebo
effects’, can be attributed to the pharma-
cological activity of excipients. For example, the
variability in the clinical ratings by trial
observers from one site to another, the
expectation or anticipation of clinical
improvement and consequent increase in
endogenous chemicals that cause self-healing
responses, empathy, conditioning,  beliefs and
social cues have all been proven to affect
clinical responses (3).
There are, however, some effects that can be
attributed to the pharmacological activity of the
excipients themselves. Such responses manifest
with greater probability in liquid dosage forms,
which utilize a broader spectrum of excipients,
than in solid dosage forms, where generic 'off-
the-shelf' placebos can be utilized.
A phase IIb clinical trial in rheumatoid arthritis
patients that utilized a methyladenosine
derivative in conjunction with methotrexate in
the active arm versus methotrexate in
conjunction with polyoxyl 45 castor oil and
Miglyol® 812 (caprylic/capric acid triglycerides)
as part of the placebo composition, found an
equally high number of responders in the
placebo arm as those in the active arm (4). It
turned out that these excipients upregulated the
adenosine receptors A3 and A2A, which are
known to attenuate the levels of endogenous
inflammatory cytokines (5).
Another placebo controlled trial that utilized
mesenchymal stem cells (MSC) for Crohn’s
disease found an unusually high response rate
for patients on the placebo arm. This was
attributed to faulty study design (6). The vehicle
in which the MSCs’ were administered, Plasma-
lyte A®, consisted of dimethyl sulfoxide
(DMSO) and albumin in water. That
inflammatory bowel diseases often manifest
with an excess generation of free radicals is well
documented in the literature along with the
ameliorative effects of radical scavengers and
antioxidants such as DMSO. It is not incon-
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ceivable that patients on the placebo arm may
have benefitted from the inclusion of DMSO in
the placebo, although it must be pointed out
that placebo administered without deception
has been shown to significantly improve
symptoms in irritable bowel syndrome as well
(7).
Cremophor® EL, a nonionic surfactant and
solubilizer present in Taxol®, has been shown
to promote cytotoxicity via calcium dependent
necrosis in murine models (8), decrease the
activity of the P-glycoprotein dependent efflux
pump, decrease the accumulation of cisplatin in
peripheral blood leucocytes (9) thereby
increasing its therapeutic index and to decrease
the nephrotoxicity and hepatotoxicity
associated with cisplatin in murine models (10).
Co-administration of Taxol and cisplatin is
therefore expected to lead to a synergistic
efficacy increase based on the aforementioned
effects of the excipient, Cremophor® EL.
Several clinical trials have demonstrated a better
outcome for patients with advanced ovarian
cancer on the paclitaxel-cisplatin regimen than
for those on a cyclophosphamide-cisplatin
regimen (11 and references therein).
Tranexamic acid, an antifibrinolytic agent in its
own right, is used to solubilize the
nonglycosylated form of recombinant tissue
plasminogen activator (tPA, a fibrinolytic agent)
in Reteplase®. It also retards the binding of tPA
to the NMDA receptors by acting as a lysine
analog (12). While no placebo controlled trials
seem to have been conducted with Reteplase®,
the inclusion of an excipient in the placebo
which is known to have a diametrically opposite
pharmacological effect to the active ingredient
can be construed as being conducive to
achieving clinical significance, were such a
clinical trial to be performed.
It is known that vaccine adjuvants such as alum
and MF59® (a squalene-in-water emulsion) have
intrinsic immune enhancing properties that act
via multiple mechanisms (13, 14). It is also
generally recognized that the weaker the
antigen, the more is the dependency on
adjuvants to provide the innate immune
triggering mechanism that elicits effective
immunogenicity (15). It can be argued that
adjuvants, by themselves, may be incapable of
eliciting adaptive immune responses in the
absence of dead or weakened pathogens or
pathogen proteins. However, where at-risk
populations can be clearly defined, there is a
greater probability of such antigens already
being present in the host (latent period) and
thus, the administration of adjuvant alone, may
be enough to trigger strong adaptive B and T
cell immune responses. In such instances, the
contribution of adjuvant that is included in the
placebo may be of such a magnitude so as to
negate the (real) effect of subunit adjuvanted
vaccines (16).
A recent article pointed out that the
composition of placebos used in clinical trials is
seldom, if ever, disclosed (17). Seemingly inno-
cuous ingredients such as chelating agents,
multivalent cations, and preservatives are
known to possess intrinsic pharmacological
effects with regard to attenuation or
amplification of bacterial growth (18). For
example, chelating agents, typically present in
pharmaceutical formulations as antioxidant or
preservative aids, scavenge metal ions which, in
some instances, may be essential for the growth
of some bacterial populations (19). On the
other hand, multivalent cations used as
solubilizers or tonicity adjustors may have the
opposite effect. Such activity may manifest
itself, in conflicting ways, depending upon the
mode of administration, concentration and
residence time (20, 21). The confounding
effects of such ingredients, when present in
conjunction with antibacterial APIs’ must be
carefully considered when designing placebo
comparator clinical trials.
Short of identifying a sugar pill being used as a
placebo for a diabetes clinical trial, it is very
difficult to extract information that is indicative
of pharmaceutical excipients, by themselves, 
functioning to modulate pharmacological
responses in placebos. Pharmacological effects
can be mediated by ‘generic’ mechanisms such
as the modulation of reactive oxygen species
and metal ions or the re-organization or
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permeability alteration of cell membrane
constituents. These also happen to be the
established mechanisms of action for various
classes of commonly used excipients.
Therefore, even if a part of the ‘placebo
response’ were to be attributed to the
pharmacological activity of the excipient, the
placebo composition could mean the difference
between the trial either crossing the futility
boundary or, demonstrating a significant API
effect.
Given what we know about pharmaceutical
excipients today, it would be very useful to
voluntarily disclose the placebo composition
used in clinical trials. Such disclosure would not
only lend more transparency to the drug
approval process, but would also provide
reviewers a chance to evaluate whether, and to
what extent, excipients in the placebo may
contribute toward the outcome. As a corollary,
placebo compositions may be designed to
minimize any confounding effects with API
efficacy. Such compositions, with appropriate
justification may, or may not contain all the
ingredients that are present in the active
formulation. Ostensible improvements in cli-
nical trial design, such as the introduction of
the sequential parallel comparison design (22),
that specifically aims to reduce the placebo
effect, must be carefully scrutinized to ensure
that placebo non-responders do not inad-
vertently constitute subpopulations that are
refractory to the excipient(s) mechanism(s) of
action(s).
The concept of the placebo as a tabula rasa, on
which the API’s signature is scribed, appears to
be an increasingly untenable proposition.
Ironically, it may have been made so, in part, 
because of the increased complexity of
emerging excipients used to deliver APIs’ to
specific pharmacological targets. Many of these
excipients possess intrinsic pharmacological
activity through well defined mechanisms.
Consequently, placebo controlled clinical trials
must factor in the excipient bioactivity as well
as disclose placebo composition, so that
pharmacological responses that are innate only
to the API, may be better discriminated.
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